A Sleep Disorder Hiding in Plain Sight
A new report in Psychiatric Times highlights a troubling pattern in mental health care: narcolepsy is far more common than clinicians recognize, and it is routinely mistaken for ADHD, major depressive disorder, or other psychiatric conditions. The result is a diagnostic delay of 10 to 15 years on average — years during which patients may receive treatments that don't address the root cause of their symptoms.
Narcolepsy is a neurological disorder caused by the loss of hypocretin-producing neurons in the hypothalamus. Its hallmark symptoms — excessive daytime sleepiness, cognitive fog, emotional blunting, low motivation, and disrupted nighttime sleep — overlap substantially with the presentation of depression and ADHD. Without a high index of suspicion and targeted sleep testing, the diagnosis is easy to miss, even in specialized psychiatric settings.
The Psychiatric Times piece emphasizes that sleep clinics themselves often fail to catch narcolepsy, partly because patients are not always referred for polysomnography or multiple sleep latency testing (MSLT) — the gold-standard diagnostic tools. Instead, they are cycled through antidepressants, stimulants, and behavioral interventions that offer partial or no relief.
Why This Matters in the Context of Ketamine Therapy
For patients pursuing ketamine infusions or esketamine (Spravato) for treatment-resistant depression, this diagnostic blind spot carries real implications. Ketamine is a powerful tool for rapidly reducing depressive symptoms, but it is not a cure for every condition that looks like depression. If a patient's primary driver of fatigue, low mood, and cognitive impairment is undiagnosed narcolepsy rather than major depressive disorder, ketamine therapy may produce only partial or short-lived improvement.
This is not a theoretical concern. Treatment-resistant depression — the population most likely to seek ketamine therapy — is, by definition, a group that has not responded adequately to standard interventions. Within that group, a meaningful subset may carry undiagnosed comorbidities or alternative diagnoses that have not yet been identified. Narcolepsy, given its symptom overlap with depression, is a plausible contributor for some of these patients.
Ketamine clinicians and referring psychiatrists should be alert to clinical signals that may point toward a sleep disorder rather than — or in addition to — a primary mood disorder. These include: excessive daytime sleepiness that is disproportionate to the patient's reported mood, sleep paralysis or hypnagogic hallucinations, cataplexy (sudden muscle weakness triggered by emotion), and a pattern of depressive symptoms that began in adolescence alongside notable sleep complaints.
Key Takeaway
If you have pursued multiple antidepressant trials or ketamine therapy with incomplete results — especially if excessive daytime sleepiness and cognitive fog are prominent symptoms — ask your provider whether a formal sleep evaluation has ever been completed. A referral for polysomnography and MSLT testing can rule out narcolepsy and other sleep disorders that may be driving your symptoms.
What Patients and Caregivers Can Do Right Now
The first and most practical step is to take a careful sleep history seriously — not just reporting how many hours you sleep, but documenting the quality and architecture of that sleep. Many patients with narcolepsy describe sleeping eight or nine hours and still waking unrefreshed. They may nap frequently without feeling rested. They may notice that their mood and energy fluctuate in ways that do not map neatly onto the standard depressive episode pattern.
Before beginning or continuing ketamine therapy, it is reasonable to ask your psychiatrist or ketamine provider directly: Have we ruled out a primary sleep disorder? This is not a confrontational question — it is a clinically appropriate one, particularly if you have a history of inadequate response to antidepressants. A good provider will welcome the inquiry.
For caregivers supporting a family member in treatment, watch for the specific symptom cluster described above. Narcolepsy often goes unrecognized partly because patients themselves normalize their symptoms over years of living with them. External observers sometimes notice the pattern more clearly.
It is also worth knowing that narcolepsy and depression can genuinely coexist. Receiving a narcolepsy diagnosis does not necessarily mean ketamine therapy is off the table — it means the treatment plan needs to address both conditions. Sodium oxybate (approved for narcolepsy) and stimulant medications used in narcolepsy management have distinct profiles from psychiatric medications, and integrating care across a sleep specialist and a ketamine-prescribing psychiatrist may be the most effective path for complex cases.
The Broader Diagnostic Challenge
The findings reported in Psychiatric Times reflect a larger structural issue in mental health care: symptom-based diagnosis without sufficient workup for neurological or medical contributors. Depression is a syndrome, not a single disease — and the treatment-resistant subset of that syndrome is almost certainly heterogeneous. Some patients have true refractory major depressive disorder. Others may have bipolar spectrum illness, autoimmune encephalitis, hypothyroidism, sleep apnea, or narcolepsy driving their presentation.
Ketamine therapy has expanded access to rapid-acting relief for many people who had run out of options. But its efficacy is maximized when it is applied to the right diagnosis. The growing awareness of narcolepsy's psychiatric camouflage is a useful reminder that thorough diagnostic evaluation — including sleep medicine when indicated — is foundational to any serious treatment-resistant depression workup.
Read the full report at Psychiatric Times.
Share